Who: Daiichi Sankyo
With: Ranbaxy
What: $4.6B buyout
Scoop: Takeda wasn't the only Japanese drugmaker to ink a billion-dollar deal. In a $4.6 billion deal, Daiichi Sanyko bought Indian powerhouse Ranbaxy. That move positions Daiichi Sankyo to become a major supplier of low-priced generics to Japan's aging population and accelerates a trend by Japanese pharma companies to enter emerging Asian markets, where they see much of their future growth. Ranbaxy, as part of Daiichi, will get to further expand its efforts to become a research-based drug developer.
Related Articles:
Daiichi Sankyo acquires Ranbaxy in $4.6B deal [1]
Daiichi aims for 60 percent growth [2]
Merck turns to Ranbaxy for $100M R&D effort
[3]Ranbaxy touts R&D abilities in new discovery pact [4]
Links:
[1] http://www.fiercebiotech.com/story/daiichi-sankyo-acquires-ranbaxy-4-6b-deal/2008-06-11
[2] http://www.fiercepharma.com/story/daiichi-aims-60-percent-growth/2007-10-02?utm_medium=rss&utm_source=pharma_Daiichi%20Sankyo&cmp-id=OTC-RSS-FP
[3] http://www.fiercebiotech.com/story/merck-turns-to-ranbaxy-for-100m-rd-effort/2008-05-12
[4] http://www.fiercebiotech.com/story/ranbaxy-touts-rd-abilities-in-new-discovery-pact/2007-02-07
[5] http://www.fiercebiotech.com/special-reports/takeda-and-millennium-billion-dollar-deals
[6] http://www.fiercebiotech.com/special-reports/2008s-billion-dollar-deals-h1
[7] http://www.fiercebiotech.com/special-reports/genzyme-and-isis-billion-dollar-deals